Trevi Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
142.4M
on 2026-06-30, from 69.0M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2025-11-13. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗
$200.0M
Leerink Partners, agreement of 2023-06-29. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-06 is not read yet.
Cash
24.2 quarters
$318.9M on 2026-06-30 ÷ $13.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-04-16 | Public offering | 11,600,000 | $13.00 | $150.8M | 424B5 ↗ |
| 2025-06-03 | Public offering | 17,400,000 | $5.75 | $100.0M | 424B5 ↗ |
| 2024-12-15 | Public offering | 12,500,000 | $4.00 | $50.0M | 424B5 ↗ |